Table 1.
Descriptive Characteristics in HCWs and Immunocompromised Participants
| Characteristic (N = 1271) |
HCWs (N = 172) (13.5%) |
Immunocompromised (N = 1099) (86.5%) | P a | Participants by Immunocompromising Condition | ||||
|---|---|---|---|---|---|---|---|---|
| SOT (N = 450) (41.0%) | Autoimmune (N = 263) (23.9%) | Hematologic Malignancy (N = 156) (14.2%) | HIV (N = 94) (8.6%) | Solid Tumor (N = 136) (12.4%) | ||||
| Age in y, mean (SD) | 44.2 (13.3) | 60.1 (13.3) | <.001 | 60.3 (13.0) | 55.3 (14.8) | 67.7 (10.3) | 57.4 (10.0) | 61.7 (12.2) |
| Age in y, n (%) | ||||||||
| 19–44 | 99 (57.6%) | 172 (15.7%) | 66 (14.7%) | 72 (27.4%) | 5 (3.2%) | 10 (10.6%) | 19 (14.0%) | |
| 45–60 | 50 (29.1%) | 300 (27.3%) | 118 (26.2%) | 76 (28.9%) | 21 (13.5%) | 49 (52.1%) | 36 (26.5%) | |
| >60 | 23 (13.4%) | 627 (57.1%) | 266 (59.1%) | 115 (43.7%) | 130 (83.3%) | 35 (37.2%) | 81 (59.6%) | |
| Sex, n (%) | <.001 | |||||||
| Female | 129 (75.0%) | 549 (50.0%) | 170 (37.8%) | 189 (71.9%) | 72 (46.2%) | 10 (10.6%) | 108 (79.4%) | |
| Male | 43 (25.0%) | 550 (50.0%) | 280 (62.2%) | 74 (28.1%) | 84 (53.8%) | 84 (89.4%) | 28 (20.6%) | |
| Race, n (%) | 0.49 | |||||||
| Non-White | 16 (9.3%) | 85 (7.7%) | 42 (9.3%) | 16 (6.1%) | 9 (5.8%) | 14 (14.9%) | 4 (2.9%) | |
| White | 156 (90.7%) | 1014 (92.3%) | 408 (90.7%) | 247 (93.9%) | 147 (94.2%) | 80 (85.1%) | 132 (97.1%) | |
| Comorbidities, n (%)b | ||||||||
| Cardiac disease | 42 (25.1%) | 694 (66.2%) | <.001 | 390 (89.2%) | 111 (44.9%) | 74 (51.4%) | 61 (66.3%) | 58 (45.0%) |
| CVD | 2 (1.2%) | 91 (8.7%) | <.001 | 58 (13.3%) | 10 (4.0%) | 12 (8.3%) | 6 (6.5%) | 5 (3.9%) |
| PVD | 0 (0.0%) | 2 (0.2%) | <.001 | 2 (0.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Pulmonary disease | 38 (22.8%) | 356 (33.9%) | 0.003 | 142 (32.5%) | 93 (37.7%) | 41 (28.5%) | 37 (40.2%) | 43 (33.3%) |
| Diabetes | 7 (4.2%) | 271 (25.8%) | <.001 | 196 (44.9%) | 24 (9.7%) | 18 (12.5%) | 24 (26.1%) | 9 (7.0%) |
| CKD | 0 (0.0%) | 338 (32.2%) | <.001 | 296 (67.7%) | 8 (3.2%) | 12 (8.3%) | 16 (17.4%) | 6 (4.7%) |
| Obesity | 89 (53.3%) | 543 (51.8%) | 0.713 | 247 (56.5%) | 120 (48.6%) | 66 (45.8%) | 43 (46.7%) | 67 (51.9%) |
| DLD | 47 (28.1%) | 598 (57.0%) | <.001 | 305 (69.8%) | 100 (40.5%) | 83 (57.6%) | 54 (58.7%) | 56 (43.4%) |
| Liver disease | 8 (4.8%) | 183 (17.4%) | <.001 | 120 (27.5%) | 28 (11.3%) | 15 (10.4%) | 13 (14.1%) | 7 (5.4%) |
| Vaccine type, n (%) | 0.19 | |||||||
| mRNA-1273 (Moderna) | 73 (42.4%) | 541 (49.2%) | 217 (48.2%) | 133 (50.6%) | 86 (55.1%) | 29 (30.9%) | 76 (55.9%) | |
| BNT162b2 (Pfizer) | 96 (55.8%) | 548 (49.9%) | 228 (50.7%) | 127 (48.3%) | 70 (44.9%) | 63 (67.0%) | 60 (44.1%) | |
| Adenovirus | 3 (1.7%) | 10 (0.9%) | 5 (1.1%) | 3 (1.1%) | 0 (0.0%) | 2 (2.1%) | 0 (0.0%) | |
| Days from second vaccine to antibody sample, median (IQR) | 132.5 (118.0,150.0) | 93.0 (69.0,118.0) | <.001 | 92.0 (68.0,118.0) | 91.0 (68.0,114.0) | 94.5 (73.0,113.0) | 85.5 (62.0,105.0) | 111.0 (84.0,133.0) |
Abbreviations: CKD, chronic kidney disease; CVD, cerebrovascular disease; DLD, dyslipidemia; HCWs, healthcare workers; HIV, human immunodeficiency virus; IQR, interquartile range; mRNA, messenger RNA; PVD, peripheral vascular disease; SOT, solid organ transplant.
P values are the comparisons between HCWs and all immunocompromised patients calculated by likelihood ratio χ2 test or Wilcoxon rank-sum test.
Comorbidities extracted from the University of Pittsburgh Medical Center electronic medical record; data available for 167 HCWs and 1049 immunocompromised participants.